For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology ...

The FTSE 100 chalked up a 12th straight day of gains yesterday, and bulls are arguably looking a little tired as we digest a slew of corporate updates this morning. The blue chips marginally in the ...

In his final article for Sky News, Ian reflects on the big stories and changes he has seen and reveals what depressed and surprised him the most while covering some of the century's biggest economic ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

FTSE 100 top-tenner GSK PLC (LSE:GSK, NYSE:GSK) has also reported earnings ahead of expectations, and kept full year guidance ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...